Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia.

Boklan JL, Walsh AM, de la Maza MC, Su LL, Nizzi FA Jr, Schafernak KT.

J Pediatr Hematol Oncol. 2018 Apr 17. doi: 10.1097/MPH.0000000000001154. [Epub ahead of print]

PMID:
29668550
2.

Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7.

Pastor VB, Sahoo SS, Boklan J, Schwabe GC, Saribeyoglu E, Strahm B, Lebrecht D, Voss M, Bryceson YT, Erlacher M, Ehninger G, Niewisch M, Schlegelberger B, Baumann I, Achermann JC, Shimamura A, Hochrein J, TedgÄrd U, Nilsson L, Hasle H, Boerries M, Busch H, Niemeyer CM, Wlodarski MW.

Haematologica. 2018 Mar;103(3):427-437. doi: 10.3324/haematol.2017.180778. Epub 2017 Dec 7.

3.

Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.

Messinger Y, Boklan J, Goldberg J, DuBois SG, Oesterheld J, Abla O, Martin A, Weinstein J, Hijiya N.

Pediatr Hematol Oncol. 2017 May;34(4):187-198. doi: 10.1080/08880018.2017.1360970. Epub 2017 Oct 17.

PMID:
29039989
4.

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.

Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B.

Clin Epigenetics. 2017 Oct 5;9:108. doi: 10.1186/s13148-017-0411-x. eCollection 2017.

5.

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26414. Epub 2017 Apr 14.

PMID:
28409853
6.

A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.

Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M.

Clin Cancer Res. 2013 Jul 1;19(13):3649-58. doi: 10.1158/1078-0432.CCR-12-3166. Epub 2013 May 9.

7.

A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.

Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendren A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC).

Pediatr Blood Cancer. 2013 Feb;60(2):230-6. doi: 10.1002/pbc.24278. Epub 2012 Sep 28.

8.

Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.

Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1252-8. doi: 10.1002/pbc.24264. Epub 2012 Aug 8.

PMID:
22887831
9.

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.

Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A.

Onco Targets Ther. 2011;4:149-68. doi: 10.2147/OTT.S21553. Epub 2011 Sep 5.

10.

Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.

Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger SP, Boklan J, Smith AA, Arceci RJ, Katzenstein HM, Harbison C, Zhou X, Lu H, Langer C, Weber M, Gore L.

J Clin Oncol. 2009 Oct 20;27(30):5102-8. doi: 10.1200/JCO.2008.20.8975. Epub 2009 Sep 21.

11.

Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells.

Gao S, Mobley A, Miller C, Boklan J, Chandra J.

Leuk Res. 2008 May;32(5):771-80. Epub 2007 Nov 26.

12.

Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.

Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM.

Clin Cancer Res. 2007 Mar 15;13(6):1783-8.

13.

Little patients, losing patience: pediatric cancer drug development.

Boklan J.

Mol Cancer Ther. 2006 Aug;5(8):1905-8. Review. No abstract available.

14.

Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts.

Boklan J, Nanjangud G, MacKenzie KL, May C, Sadelain M, Moore MA.

Cancer Res. 2002 Apr 1;62(7):2104-14.

15.

Lung transplantation after allogeneic marrow transplantation in pediatric patients: the Memorial Sloan-Kettering experience.

Heath JA, Kurland G, Spray TL, Kernan NA, Small TN, Brochstein JA, Gillio AP, Boklan J, O'Reilly RJ, Boulad F.

Transplantation. 2001 Dec 27;72(12):1986-90.

PMID:
11773900

Supplemental Content

Loading ...
Support Center